Sinopharm Group Co L (SHTDF) 4.3400 $SHTDF Week In

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sinopharm Group Co L (SHTDF) 4.3400 $SHTDF

Week In Review: China's Innovent Raises $100 Million For Biologics Portfolio
ChinaBio Today - at Seeking Alpha - Sun Jan 25, 7:04AM CST
Deals and Financings Innovent Biologics of Suzhou announced a significant $100 million C round funding, which the company will use to advance its portfolio of eight biologic drug candidates. Founded in 2011, Innovent already has filed four IND...
CTLT: 30.43 (+1.11), PKI: 52.16 (+0.38)

Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
Business Wire - Fri Nov 14, 5:00AM CST
Provectus Biopharmaceuticals, Inc. (NYSE MKT VCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus" , announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.
PVCT: 0.87 (-0.01)

Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
PR Newswire - Wed Oct 22, 6:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
PVCT: 0.87 (-0.01)

Global and Chinese Chemical Reagent Industry Report 2014-2017
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sjcjmv/global_and) has announced the addition of the "Global and Chinese Chemical Reagent Industry Report, 2014-2017" report to their offering. Chemical reagent, purified from industrial chemicals, serves chiefly scientific experiment and detection analysis, and finds massive application in electronic information, medicine, food, aerospace and military industry manufacturing. In 2013, global chemical reagent market was worth about USD 13.6 billion, with market demand concentrated in United States, Europe and Japan. There are a large variety of chemical reagents, totaling above 250,000 around the world. American Sigma-Aldrich is the company that produces the most varieties of chemical reagents, up to approximate 230,000. Global chemical reagent industry characterizes a fairly high concentration, and American Sigma-Aldrich and German Merck Group, as industry leaders, took up a combined 30% or so market share globally in 2013. China chemical reagent industry has developed quickly, achieving a CAGR of 15.9% as concerns market size during 2007-2013, and making up 19.2% of global market size. Chemical reagent can be divided into general reagent and high-purity reagent, with the latter accounting for about 26% of total market size in China in 2013. High-purity chemical reagent is mainly used in semiconductor industry, and is the product that enjoys the fastest growth rate and has the highest technical content and added value. With the rapid development of China's electronic information, biotechnology, national defense, military industry and other industries, the demand for high purity reagent will keep a roughly 15% growth rate over the next couple years. In 2013, there were more than 400 chemical reagent producers with production licenses in China, most of which focused on low-end products, resulting in fierce competition in the low-end market; by contrast, the high-end market is dominated by transnational companies, such as German Merck Group and American Sigma-Aldrich, which held a combined 16.9% market share in China in 2013. In recent years, concentration of China chemical reagent industry has been improving gradually, mainly reflected by rapid development of large chemical reagent companies. Moreover, China-made chemical reagents are advancing from the low-end to the middle and high-end, with some imported products having been substituted with domestic ones. Typical domestic companies include Xilong Chemical Co., Ltd. and Sinopharm Chemical Reagent Co., Ltd., together occupying 13.2% of the Chinese market in 2013. Key Topics Covered: 1. Overview of Chemical Reagent 2. Chemical Reagent Market 3. Chinese Chemical Reagent Market 4. Foreign Companies 5. Chinese Companies 6. Summary and Forecast Companies Mentioned - Anhui Fulltime Specialized Solvent & Reagent - Danaher - Guangdong Guanghua Sci-Tech - Jianghua Microelectronics Materials - Jiangyin Chemical Reagent Factory - Johnson Matthey - Merck Group - Sigma-Aldrich - Sinopharm Group - Suzhou Crystal Clear Chemical - Suzhou JIMCEL Electronic New Material - TCI - Thermo Fisher - Wako - Xilong Chemical For more information visit http://www.researchandmarkets.com/research/sjcjmv/global_and
MRK: 60.23 (+0.45), DHR: 86.45 (-1.39)

Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
BSPM: 1.36 (-0.01), BAX: 69.36 (+0.32), PFE: 33.99 (+0.05), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), SVA: 5.36 (-0.25), SNY: 50.52 (-0.27), CPHI: 0.34 (-0.01)

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.
Business Wire - Mon Aug 18, 8:19AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus" , announced today that it entered into a Memorandum of Understanding ("MOU" with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI" , the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK" , the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.
PVCT: 0.87 (-0.01)

China to Host World's Largest Integrated Health Industry Event "tHIS" in 2015
Business Wire - Wed Jun 25, 4:00AM CDT
Reed Sinopharm Exhibitions, the leading healthcare event organizer in China, announced Wednesday the launch of The Health Industry Summit (tHIS) in Shanghai. This new event, to be held 15-18 May 2015 at National Exhibition and Conference Center (Shanghai), the world's largest single block exhibition complex, will combine a Summit program of over 100 conferences with a gigantic 260,000 sqm exhibition area through co-locating three of the leading health industry exhibitions, namely CMEF, PHARMCHINA, API CHINA, effectively forming the world's largest integrated health industry event.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 34

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 157

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 112

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 140

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 79

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell plc Announces Strategic Share Buybacks Amid Market Moves

Updated Category News Views 250

Shell plc Engages in Significant Share Buybacks Transaction in Own Shares Shell plc, a global leader in energy and petrochemical sectors, has undertaken a strategic initiative involving the purchase of its own shares for cancellation to optimize its capital structure. This decision aligns with the company’s broader strategy to enhance shareholder value through various...

Continue Reading
CSL Seqirus Strengthens Pandemic Readiness with New BARDA Award

Updated Category News Views 280

CSL Seqirus Receives Significant BARDA Award CSL Seqirus has recently received a noteworthy award from the Biomedical Advanced Research and Development Authority (BARDA). This grant is aimed at furthering the company's capabilities in preparing for potential pandemic situations through the development of avian influenza vaccines. The need for preparedness in public health...

Continue Reading
Navient’s Third Quarter Results: Financial Performance Insights

Updated Category News Views 86

Navient Announces Third Quarter 2024 Financial Results HERNDON, Va. — Navient (Nasdaq: NAVI) shared its third quarter financial results for 2024, showcasing the company’s ongoing commitment to providing innovative financial services and solutions. The comprehensive financial results are listed on the company's official site, ensuring transparency and accessibility for...

Continue Reading
Comstock Inc. Unveils Insights from 3Q24 Stakeholder Analysis

Updated Category News Views 169

Comstock Inc. (NYSE: LODE) dropped its Q3 2024 Stakeholder Perception Analysis Report, and you know how these things go—traders squinted at the numbers while trying to decipher what the hell it meant for their investments. So here's the deal: Comstock put out this report to show how its stakeholders felt about its performance and strategy, but really, it raised more...

Continue Reading
GraniteShares Unveils Innovative YieldBOOST Fund-of-Funds ETFs

Updated Category News Views 370

GraniteShares Introduces Unique Fund-of-Funds ETFs GraniteShares, an innovative leader in the ETF space, has recently introduced two new YieldBOOST Fund-of-Funds ETFs. These expansions reflect their commitment to offering cutting-edge investment solutions that cater to the evolving needs of investors. What Are the New ETFs? The two new offerings are the GraniteShares...

Continue Reading